132 related articles for article (PubMed ID: 21860256)
1. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.
Musher DM; Manoff SB; McFetridge RD; Liss CL; Marchese RD; Raab J; Rueda AM; Walker ML; Hoover PA
Hum Vaccin; 2011 Sep; 7(9):919-28. PubMed ID: 21860256
[TBL] [Abstract][Full Text] [Related]
2. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
Musher DM; Manof SB; Liss C; McFetridge RD; Marchese RD; Bushnell B; Alvarez F; Painter C; Blum MD; Silber JL
J Infect Dis; 2010 Feb; 201(4):516-24. PubMed ID: 20092407
[TBL] [Abstract][Full Text] [Related]
3. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years.
Manoff SB; Liss C; Caulfield MJ; Marchese RD; Silber J; Boslego J; Romero-Steiner S; Rajam G; Glass NE; Whitney CG; Carlone GM
J Infect Dis; 2010 Feb; 201(4):525-33. PubMed ID: 20088694
[TBL] [Abstract][Full Text] [Related]
4. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
[TBL] [Abstract][Full Text] [Related]
5. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years.
Goldblatt D; Southern J; Andrews N; Ashton L; Burbidge P; Woodgate S; Pebody R; Miller E
Clin Infect Dis; 2009 Nov; 49(9):1318-25. PubMed ID: 19814624
[TBL] [Abstract][Full Text] [Related]
6. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.
Grabenstein JD; Manoff SB
Vaccine; 2012 Jun; 30(30):4435-44. PubMed ID: 22542818
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
[TBL] [Abstract][Full Text] [Related]
11. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness.
Hammitt LL; Bulkow LR; Singleton RJ; Nuorti JP; Hummel KB; Miernyk KM; Zanis C; Whaley M; Romero-Steiner S; Butler JC; Rudolph K; Hennessy TW
Vaccine; 2011 Mar; 29(12):2287-95. PubMed ID: 21255685
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.
de Roux A; Schmöle-Thoma B; Siber GR; Hackell JG; Kuhnke A; Ahlers N; Baker SA; Razmpour A; Emini EA; Fernsten PD; Gruber WC; Lockhart S; Burkhardt O; Welte T; Lode HM
Clin Infect Dis; 2008 Apr; 46(7):1015-23. PubMed ID: 18444818
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
[TBL] [Abstract][Full Text] [Related]
14. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life.
Silfverdal SA; Skerlikova H; Zanova M; Papúchová D; Traskine M; Borys D; Schuerman L
Pediatr Infect Dis J; 2011 Sep; 30(9):e155-63. PubMed ID: 21572373
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years.
Schwarz TF; Flamaing J; Rümke HC; Penzes J; Juergens C; Wenz A; Jayawardene D; Giardina P; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2011 Jul; 29(32):5195-202. PubMed ID: 21619909
[TBL] [Abstract][Full Text] [Related]
16. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial.
O'Brien KL; Moisi J; Moulton LH; Madore D; Eick A; Reid R; Weatherholtz R; Millar E; Hu D; Hackell J; Kohberger R; Siber G; Santosham M
J Infect Dis; 2007 Jul; 196(1):104-14. PubMed ID: 17538890
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
Ruiz-Palacios GM; Guerrero ML; Hernández-Delgado L; Lavalle-Villalobos A; Casas-Muñoz A; Cervantes-Apolinar Y; Moreira M; Schuerman L
Hum Vaccin; 2011 Nov; 7(11):1137-45. PubMed ID: 22048109
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
[TBL] [Abstract][Full Text] [Related]
19. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.
Søgaard OS; Lohse N; Harboe ZB; Offersen R; Bukh AR; Davis HL; Schønheyder HC; Østergaard L
Clin Infect Dis; 2010 Jul; 51(1):42-50. PubMed ID: 20504165
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]